PhaseBio plans to seek FDA approval for lead drug in Q4; shares surge

PhaseBio Pharmaceuticals

16/05/2022 11:55

** Shares of PhaseBio Pharmaceuticals  PHAS.O  surge 11.6%
to $1.15 premarket
    ** Drug developer expects to seek U.S. FDA approval for its
lead drug, bentracimab, by early Q4 2022  urn:newsml:reuters.com:*:nBw5B1GJfa
    ** Adds FDA indicated willingness to accept a application
with data from 25-30 uncontrolled bleeding patients, in addition
to surgical patients enrolled to date, which would potentially
support approval for both surgical and uncontrolled bleeding
indications
    ** All five brokerages covering PHAS rate the stock "buy" or
higher; their median PT is $15
    ** Up to last close, stock down 60.5% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))